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1 Drug description 
Generic/Brand name/ATC code:  
Regorafenib/Stivarga®/L01XE21 
Developer/Company:  
Bayer Pharma AG 
Description:  
Regorafenib (Stivarga®) is a multi-kinase inhibitor that targets angiogenic, 
stromal and oncogenic receptor tyrosine kinases [1]. It binds to vascular en-
dothelial growth factor receptors (VEGFRs) 2 and 3, which are important for 
tumor angiogenesis, and to receptor tyrosine kinases RET, KIT, PDGFR 
and RAF, which are involved in tumor cell signaling. Regorafenib thus in-
hibits tumor angiogenesis and tumor cell proliferation [2]. 
Regorafenib is administered at a dosage of 160 mg (four 40 mg tablets), once 
daily for the first 21 days of each 28-day cycle. The drug has to be taken oral-
ly, due to effects on pharmacokinetics, with a low-fat breakfast. The treat-
ment should be continued until disease progression or unacceptable toxicity 
occurs [3]. 
 
2 Indication 
Regorafenib (Stivarga®) is indicated in patients with metastatic colorectal 
cancer (mCRC) who have been previously treated with: 
 a fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy 
 an anti-VEGF therapy 
 an anti-EGFR therapy (if KRAS wild-type) [3]. 
 
3 Current regulatory status 
In August 2013, the EMA granted marketing authorization for Stivarga® for 
the treatment of adult patients with mCRC who have been previously treat-
ed with, or are not considered candidates for, available therapies (including  
fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR 
therapy) [4]. 
The FDA approved regorafenib (Stivarga®) on September 27, 2012 [5] for 
patients with mCRC who have been pretreated with: 
 A fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy 
 an anti-VEGF therapy 
 an anti-EGFR therapy (if KRAS wild-type).  
  
regorafenib inhibits 
tumor angiogenesis and 
tumor cell proliferation  
 
 
 
oral administration 
for heavily pretreated  
patients with mCRC 
approved by the EMA 
and the FDA 
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In February 2013, the FDA approved regorafenib (Stivarga®) for the treat-
ment of patients with advanced gastrointestinal stromal tumors (GIST) that 
cannot be surgically removed and no longer respond to other FDA-approved 
treatments for this disease [6].  
In Switzerland, Stivarga® has been approved for the treatment of patients 
with mCRC who were previously treated with a fluoropyrimidine-, oxali-
platin- and irinotecan-based therapy, anti-VEGF therapy and anti-EGFR (in 
case of KRAS wild-type) on February 27, 2013 [7]. In Japan, marketing au-
thorization for Stivarga® for the treatment of unresectable advanced or re-
current colorectal cancer was granted on March 25, 2013 [8]. 
 
4 Burden of disease 
Colorectal cancer (CRC) develops in the tissues of the colon and/or rectum. It 
is the third most common cancer in men and women in the western countries.  
Due to early detection and treatment, incidence rates are declining [9]. In 
Austria, CRC is the third most common malignancy diagnosed in men and the 
second most common malignancy diagnosed in women. In 2010, the incidence 
rate in Austria for both men and women was 28.1 (per 100,000 people per 
year), mortality rate was 11.9 (per 100,000 people per year) [10]. 
Median age at diagnosis for CRC is about 69 years [11]; the 1-year relative 
survival rate for persons with CRC is 84% and the 5-year relative survival rate 
is 64% (relative survival compares survival among cancer patients to that of 
people not diagnosed with cancer who are of the same age, race and sex) [9]. 
Histologically, more than 95% of CRCs are adenocarcinomas. Less common 
types are carcinoid tumors, gastrointestinal stromal tumors, lymphomas or 
sarcomas [12]. 
Risk factors for CRC are increasing age, a personal or family history of CRC 
and/or polyps, a personal history of chronic inflammatory bowel disease as 
well as hereditary conditions (for example Lynch syndrome and familial ade-
nomatous polyposis). Moreover, type 2 diabetes, obesity, physical inactivity, a 
diet high in red or processed meat, alcohol consumption, long-term smoking 
and possibly very low intake of fruit and vegetables are associated with an in-
creased risk for CRC. There are factors that appear to decrease the risk, such 
as the consumption of milk and calcium or higher blood levels of vitamin D 
[9]. 
Common symptoms of CRC are bloody or tarry stool, abdominal pain, other-
wise unexplained iron deficiency anemia and/or changes in bowel habits. Less 
common symptoms are abdominal distension, and/or nausea and vomiting. 
Straining to defecate, rectal pain or small-caliber stools indicate that the tu-
mor is located in the rectum. CRC is a potentially metastatic disease; the most 
frequently affected sites are the regional lymph nodes, the liver, the lungs and 
the peritoneum. Approximately 20% of patients have metastases at the time of 
diagnosis. The preferred staging system for CRC is the TNM classification: 
primary tumor (T), regional lymph node (N), distant metastasis (M) [13]. 
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5 Current treatment 
A large number of treatment options are available for CRC. Selection of 
therapy depends on the site and extent of metastatic disease, performance 
status, organ function and comorbidity of the patient [14]. 
If patients qualify for intensive therapy, options for the treatment of ad-
vanced or metastatic disease are the following [15]: 
 FOLFOX (fluorouracil, leucovorin, oxaliplatin) ± bevacizumab 
 CapeOX (capecitabine, oxaliplatin) ± bevacizumab  
 FOLFOX ± panitumumab (KRAS wild-type gene only) 
 FOLFIRI (fluorouracil, leucovorin, irinotecan) + bevacizumab 
 FOLFIRI ± cetuximab or panitumumab (KRAS wild-type 
gene only) 
 5-FU/leucovorin or capecitabine ± bevacizumab 
 FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, irinotecan) 
In case of disease progression after these first-line therapies, treatment op-
tions will be selected according to the first-line regimen and include: 
 FOLFIRI ± bevacizumab  
 FOLFIRI ± ziv-aflibercept 
 Irinotecan ± bevacizumab 
 Irinotecan ± ziv-aflibercept 
 FOLFIRI ± cetuximab or panitumumab (KRAS wild-type 
gene only) 
 Cetuximab or panitumumab (KRAS wild-type gene only) + 
irinotecan 
 FOLFOX ± bevacizumab 
 CapeOX ± bevacizumab 
Therapy after second progression will again depend on previously used reg-
imens and include:  
 Cetuximab or panitumumab + irinotecan 
 FOLFOX or CapeOX 
 Regorafenib 
 Clinical trial 
 Best supportive care (BSC) 
For later lines of therapy, the remaining treatment options are limited: 
 Clinical trial  
 BSC [15].  
 
 
options for first-line 
therapy 
options after first 
progression 
for further lines of 
therapy 
very few options for 
heavily pre-treated 
patients  
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6 Evidence 
A literature search was conducted on the 13 th of June 2013 in four data-
bases (Medline, Embase, CRD, and The Cochrane Library). Search terms 
were “Colorectal Neoplasms/Cancer”, “(Neoplasm) Metastasis”, “Regora-
fenib”, “Stivarga” and “bay 73”.  
Also, the manufacturer was contacted for any further evidence, and sub-
mitted 24 studies. Of these, 16 had already been identified by the system-
atic literature search, resulting in 8 additional references. 
Overall, 87 references were identified of which two have been included in 
this report: 
 a phase III study, assessing the effect of regorafenib on patients 
with mCRC that keeps progressing after administration of all ap-
proved standard therapies (CORRECT trial) [16] and 
 a meta-analysis, evaluating the risk of hand-foot skin reactions in 
patients treated with regorafenib [17]. 
 
 
6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an 
international, multicentre, randomised, placebo-controlled, phase 3 trial [16]. 
Study  
identifier 
NCT01103323, EudraCTNumber: 2009-012787-14, CORRECT trial 
Design International, multicenter, randomized (2:1 ratio), placebo-controlled 
Duration  Enrolment: 2010-04-30 to 2011-03-22 
Median follow-up: NA 
Cut-off dates for second interim analyses: 2011-07-21 
Hypothesis Superiority 
(90% power to detect a 33.3% increase in median OS, assuming a 4.5 month median 
OS for the placebo group (i.e. HR of 0.75 for regorafenib over placebo)) 
Funding Bayer HealthCare Pharmaceuticals 
Treatment 
groups 
Intervention  
(N=505) 
Regorafenib 160 mg (oral) once daily for the first 3 weeks of   
each 4-week cycle + BSC   (excluding other investigational 
antitumor agents or neoplastic chemotherapy, hormonal 
therapy, and immunotherapy) 
Control 
(N=255) 
Placebo once daily for the first 3 weeks of each 4-week cycle + 
BSC (excluding other investigational antitumor agents or neo-  
plastic chemotherapy, hormonal therapy, and immunotherapy) 
Endpoints 
and 
definitions 
Overall survival 
(primary outcome) 
OS   Time from randomization to death from any cause 
Progression-free 
survival 
PFS Time from randomization to first radiological or clinical 
observation of disease progression or death from any 
cause 
Objective tumor 
response rate 
ORR Proportion of patients with complete or partial 
response 
 
 
 
 
 
one phase III study and 
one meta-analysis 
included 
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Endpoints 
and 
definitions 
Disease control 
rate 
DCR Proportion of patients with a best response of complete 
or partial response or stable disease; assessment of stable 
disease had to be made at least 6 weeks after 
randomization 
Safety - - 
Duration of 
response and 
stable disease 
DOR NA 
Health-related 
quality-of-life and 
health utility 
values 
Hr- 
QoL 
Measured with: 
 EORTC general health status and QLQ-C30 
 EQ-5D 
 EQ-5D VAS 
Results and analysis 
Analysis  
description 
  Intention-to-treat analysis 
OS  and PFS: compared between treatment groups with stratified log-rank test 
HRs (with 95% CI) were calculated with Cox model (adjusting for stratification 
factors); Kaplan-Meier survival estimates were calculated for each treatment group 
Objective response and disease control rates were compared between treatment 
groups with Cochran-Mantel-Haenszel test (adjusting for stratification factors) 
Analysis  
population 
Inclusion  Histological or cytological documentation of adenocarcinoma 
of the colon or rectum 
 Prior locally and currently approved standard therapies 
including fluoropyrimidine, oxaliplatin, irinotecan, beva-
cizumab and cetuximab or panitumumab (if KRAS wild-type)  
 Disease progression during or within 3 months following the 
last administration of approved standard therapy or 
discontinuation of standard therapy because of unacceptable 
toxic effects 
 Measurable or non-measurable disease according to Response 
Evaluation Criteria in Solid Tumors criteria, Version 1.1 
 ECOG performance status of ≤1 
 Life expectancy of at least 3 months 
 Adequate bone-marrow, liver and renal function at the start of 
the trial 
Exclusion  Prior treatment with regorafenib 
 Previous assignment to treatment during this study 
 Previous or concurrent cancer that is distinct in primary site or 
histology from CRC within 5 years before randomization 
except for curatively treated cervical cancer in situ, non-
melanoma skin cancer and superficial bladder tumors 
 Major surgical procedures, open biopsy or significant traumatic 
injury within 28 days before start of study medication 
Characteristics  Intervention Control 
Median age/IQR, years 61/54-67 61/54-68 
Sex, % 
male/female  
 
62/38 
 
60/40 
ECOG performance 
Status, % 
0/1 
 
  
52/48 
 
 
57/43 
Primary site of disease 
Colon/rectum/colon and 
rectum, % 
64/30/6 68/27/5 
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Analysis  
population 
Characteristics KRAS mutation, % 
no/yes/unknown  
 
41/54/5 
 
37/62/2 
BRAF mutation, % 
no/yes  
 
96/4 
 
98/2 
Adenocarcinoma, % 98 96 
Number of previous 
systemic anticancer 
therapies, % 
1-2/3/≥4  
 
 
 
27/25/49 
 
 
 
25/28/47 
Previous 
Bevacizumab, % 
 
100 
 
100 
Time from diagnosis of 
metastasis  
(median, months)/IQR 
 
 
31/21-43                 
 
 
30/20-46 
Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Intervention  
(Regorafenib + BSC) 
Control 
(Placebo + BSC) 
Number of subjects N = 505 N = 255 
OS 
    median, months 
    IQR 
 
6.4 
3.6-11.8 
 
5.0 
2.8-10.4 
OS rate, % 
   at 3/6/9/12 months 
 
80.3/52.5/38.2/24.3 
 
72.7/43.5/30.8/24.0 
PFS 
    median, months 
    IQR 
 
1.9 
1.6-3.9 
 
1.7 
1.4-1.9 
  Objective response rate, % 1.0 0.4 
Duration of stable disease 
   median, months 
   IQR 
 
2.0 
1.7 - 4.0 
 
1.7 
1.4 - 1.9 
Disease control rate, % 41 15 
EORTC QLQ-C30, score  
   at baseline 
   at end of treatment 
 
62.6 
48.9 
 
64.7 
51.9 
EQ-5D, score 
   at baseline 
   at end of treatment 
 
0.73 
0.59 
 
0.74 
0.59 
EQ-5D, VAS score 
   at baseline 
   at end of treatment 
 
65.4 
55.5 
 
65.8 
57.3 
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Effect 
estimate per 
comparison 
 
Comparison groups  Intervention vs Control 
OS HR 0.77 
95% CI 0.64-0.94 
P value 0.0052 
OS in subgroup colon 
cancer 
HR 0.70 
95% CI 0.56-0.89 
P value NR 
OS in subgroup rectal 
cancer 
HR 0.95 
95% CI 0.63-1.43 
P value NR 
PFS HR 0.49 
95% CI 0.42-0.58 
P value <0.0001 
PFS in subgroup colon 
cancer 
HR 0.55 
95% CI 0.45-0.67 
P value NR 
PFS in subgroup rectal 
cancer 
HR 0.45 
95% CI 0.33-0.62 
P value NR 
ORR HR NR 
95% CI NR 
P value 0.19 
DCR HR NR 
95% CI NR 
P value P<0.0001 
Abbreviations: BRAF = B-type Raf kinase, BSC = best supportive care, CI = confidence interval, CRC = colorectal cancer, 
ECOG = Eastern Cooperative Oncology Group, EORTC = European Organisation for Research and Treatment of Cancer, EQ-
5D = EuroQol five dimension, HR = hazard ratio, IQR = interquartile range, KRAS = Kirsten rat sarcoma, NA = not avail-
able, NCT = National Clinical Trial, NR = not reported, OS = overall survival, ORR = overall response rate, PFS = progres-
sion-free survival, QLQ-C30 = quality-of-life questionnaire, VAS= visual analogue scale  
Horizon Scanning in Oncology 
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Table 2: Most frequent adverse events (occurring in ≥5% of patients in either group from start of treatment to 30 days 
after end of treatment, safety population) 
NCT01103323 
Adverse Event 
(according to NCI-
CTCAE version 3.0) 
Regorafenib + BSC (N=500) Placebo + BSC (N=253) 
Any grade 
n (%) 
Grade 3 
 n (%) 
Grade 4 
n (%) 
Any Grade 
n (%) 
Grade 3 
n (%) 
Grade 4 
n (%) 
Any event 465 (93) 253 (51) 17 (3) 154 (61) 31 (12) 4 (2) 
Fatigue 237 (47) 46 (9)  2 (<1) 71 (28) 12 (5) 1 (<1) 
Hand-foot skin 
reaction 
233 (47) 83 (17) 0 19 (8) 1 (<1) 0 
Diarrhea 169 (34) 35 (7) 1 (<1) 21 (8) 2 (1) 0 
Anorexia 152 (30) 16 (3) 0 39 (15) 7 (3) 0 
Voice changes 147 (29) 1 (<1) 0 14 (6) 0 0 
Hypertension 139 (28) 36 (7) 0 15 (6) 2 (1) 0 
Oral mucositis 136 (27) 15 (3) 0 9 (4) 0 0 
Rash or 
desquamation 
130 (26) 29 (6) 0 10 (4) 0 0 
Nausea 72 (14) 2 (<1) 0 28 (11) 0 0 
Weight loss 69 (14) 0 0 6 (2) 0 0 
Fever 52 (10) 4 (1) 0 7 (3) 0 0 
Constipation 42 (8) 0 0 12 (5) 0 0 
Dry skin 39 (8) 0 0 7 (3) 0 0 
Alopecia 36 (7) 0 0 1 (<1) 0 0 
Taste alteration 35 (7) 0 0 5 (2) 0 0 
Vomiting 38 (8) 3 (1) 0 13 (5) 0 0 
Sensory neuropathy 34 (7) 2 (<1) 0 9 (4) 0 0 
Nose bleed 36 (7) 0 0 5 (2) 0 0 
Dyspnea 28 (6) 1 (<1) 0 4 (2) 0 0 
Muscle pain 28 (6) 2 (<1) 0 7 (3) 1 (<1) 0 
Headache 26 (5) 3 (1) 0 8 (3) 0 0 
Pain, abdomen 25 (5) 1 (<1) 0 10 (4) 0 0 
Thrombocytopenia 63 (13) 13 (3) 1 (<1) 5 (2) 1 (<1) 0 
Hyperbilirubinemia 45 (9) 10 (2) 0 4 (2) 2 (1) 0 
Proteinuria 35 (7) 7 (1) 0 4 (2) 1 (<1) 0 
Anemia 33 (7) 12 (2) 2 (<1) 6 (2) 0 0 
Hypophosphatemia 25 (5) 19 (4) 0 1 (<1) 1 (<1) 0 
Abbreviations: NCI= National Cancer Institute, CTCAE= Common Terminology Criteria for Adverse Events 
 
The aim of the CORRECT trial, an international, multicenter, placebo-
controlled phase III trial, was to assess the efficacy and safety of regorafenib 
in patients with mCRC that progressed after administration of approved 
standard therapies. A total of 760 patients were randomized to receive either 
regorafenib (N=505) plus BSC or placebo (N=255) plus BSC. Regorafenib 
was administered orally at a daily dosage of 160 mg for the first three weeks 
of each 4-week cycle; mean duration of treatment was 2.8 months for the 
regorafenib group and 1.8 months for the placebo group.  
 
efficacy and safety of 
regorafenib were 
evaluated in 760  
heavily pretreated 
patients  
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Patients in both groups had a median age of 61 years and ECOG perfor-
mance status ≤1 was an inclusion criterion. Enrolled patients were heavily 
pretreated with a median number of 3 prior lines of therapy. 25% of patients 
(regorafenib group) and 28% of patients (placebo group) had 3, 49% of pa-
tients in the regorafenib group and 47% of patients in the placebo group re-
ceived ≥4 previous systemic anticancer therapies and all patients had had 
previous anti-VEGF treatment with bevacizumab. In the placebo group, 
more patients progressed on previous treatment with bevacizumab, irinotec-
an and oxaliplatin than in the regorafenib group. There was a lower propor-
tion of patients with a KRAS mutation in the regorafenib group: 54% of pa-
tients assigned to regorafenib and 62% assigned to placebo. 4% of regoraf-
enib group patients and 2% of placebo group patients showed BRAF muta-
tions. Histologically, 98% (regorafenib group) and 96% (placebo group) of 
patients had adenocarcinomas. The primary endpoint of this trial was OS; 
secondary endpoints were PFS, objective tumor response rate, disease con-
trol rate and safety. Duration of response and stable disease, health-related 
quality-of-life and health utility values were determined as tertiary end-
points. During the study, plasma and tissue samples were collected for bi-
omarker analysis within a substudy.  
Median OS was 6.4 months in the regorafenib group compared to 5.0 months 
in the placebo group (HR=0.77, 95% CI 0.64-0.94, p=0.0052). Median PFS 
was 1.9 months in the regorafenib arm and 1.7 months in the placebo arm 
(HR=0.49, 95% CI 0.42-0.58, p<0.0001). The OS rate after 3 months of 
regorafenib treatment was 80.3% compared to 72.7% in placebo group pa-
tients. After 6 months, the OS rate was 52.5% in the regorafenib group and 
43.5% in the placebo group. After 9 months, the rates were 38.2% in the 
regorafenib arm and 30.8% in the placebo arm. After 12 months of treat-
ment, the OS rate in both groups was much the same (24.3% in the regoraf-
enib group, 24.0% in the placebo group).   
Subgroup analysis according to site of disease showed better results for 
regorafenib on OS in patients with colon cancer (HR=0.70, 95%CI 0.56-
0.89) than in those with rectal cancer (HR=0.95, 95% CI 0.63-1.44). Howev-
er, regorafenib had almost the same effect on PFS in patients with colon 
cancer (HR=0.55, 95% CI 0.45-0.67) as in patients with rectal cancer 
(HR=0.45, 95% CI 0.33-0.62).  
Objective response rates were 1.0% for the regorafenib group and 0.4% for 
the placebo group, no patients achieved complete response. 41% of patients 
of the regorafenib arm and 15% of placebo arm patients achieved disease 
control. The median duration of stable disease was 2.0 months in patients 
assigned to regorafenib and 1.7 months in patients assigned to placebo. 
Overall, treatment-related adverse events occurred in 93% (regorafenib 
group) and 61% (placebo group) of patients, mostly during treatment cycles 
1-2. Grade 3 or 4 treatment-related adverse events were reported in 54% 
(regorafenib group) and 14% (placebo group). Within the regorafenib group, 
the most frequent adverse events of any grade were fatigue and hand-foot 
skin reaction, the most frequent adverse events of grade 3 or higher were 
hand-foot skin reaction, fatigue, diarrhea, hypertension and rash or desqua-
mation. Within the placebo group, the most frequent adverse events of any 
grade were fatigue and anorexia. Serious adverse events occurred in 44% of 
patients in the regorafenib arm and in 40% of patients in the placebo arm. 
During the study, a total of 110 deaths were reported (14% in the regoraf-
enib group, 16% in the placebo group), most of them caused by progression 
 
median age of 61 years 
and ECOG performance 
status ≤1 
 
49% (regorafenib 
group) and 47% 
(placebo group) of 
patients received ≥4 
previous systemic 
anticancer therapies 
 
median OS was 
extended by 1.4 months 
in the regorafenib group 
ORR was 1.0% in the 
regorafenib group 
higher rate of 
treatment-related 
adverse events of 93% 
in regorafenib group 
vs. 61% in placebo 
group 
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of underlying disease (12% in regorafenib group, 14% in placebo group). 8 
(2%) cases of death in the regorafenib group were attributed to adverse 
events: pneumonia, gastrointestinal bleeding, intestinal obstruction, pulmo-
nary hemorrhage, seizure and sudden death. In the placebo group, 3 (1%) 
patients died of pneumonia and sudden death. Liver function tests showed a 
higher incidence of increased liver transaminases and bilirubin in the 
regorafenib group; one case compatible with drug-induced liver injury due 
to regorafenib was reported. 
Adverse events were the most common cause leading to dose modification 
(= dose reduction or dose interruption) in 76% (regorafenib group) and 38% 
(placebo group) of patients. Most frequently, dermatological, gastrointesti-
nal, constitutional, metabolic or laboratory events were causes for dose  
modification. 
Health-related quality-of-life and health utility values were evaluated by: 
 European Organisation for Research and Treatment of Cancer 
(EORTC) general health status and quality-of-life questionnaire 
QLQ-C30 (possible score: 0-100, higher scores represent better 
health-related quality of life). At baseline, mean EORTC QLQ-C30 
scores were 62.6 in the regorafenib group and 64.7 in the placebo 
group. At the end of the treatment, mean scores were 48.9 in the 
regorafenib group and 51.9 in the placebo group. 
 EQ-5D (EuroQol five dimension) index questionnaire, where high-
er scores represent better health status. Analysis at baseline showed 
mean EQ-5D index scores of 0.73 (regorafenib group) and 0.74 
(placebo group) versus 0.59 in both groups at the end of the treat-
ment.  
 EQ-5D visual analogue scale evaluation showed scores of 65.4 
(regorafenib group) and 65.8 (placebo group) at baseline and 55.5 
(regorafenib group) versus 57.3 (placebo group) at the end of the 
treatment. 
 
 
6.2 Safety – further studies 
This meta-analysis evaluated the overall incidence and the risk of develop-
ing hand-foot skin reaction (HFSR) in patients treated with regorafenib 
[17]. A systematic literature search was conducted and three phase II and 
two phase III trials (both placebo-controlled) were included in the analysis; 
data of 1,078 patients having received regorafenib for the treatment of hepa-
tocellular carcinoma, GIST, renal-cell carcinoma and CRC were analyzed. 
750 of 1,078 patients received regorafenib as a single agent. In four of five 
included trials, patients had been pretreated with one or more drugs that 
could induce HFSR, of which were listed imatinib, sunitinib, bevacizumab, 
sorafenib and fluoropyrimidines. 
The overall incidence of all-grade HFSR was 60.5% (95% CI: 48.3-71.6), the 
overall incidence of high-grade HFSR was 20.4% (95% CI: 15.4-26.6). Con-
cerning tumor type, the incidence of HFSR varied significantly; the highest 
incidence was found in patients with renal-cell carcinoma, the lowest in pa-
tients with mCRC.  
health-related quality-
of-life and health utility 
values  
 
 
meta-analysis evaluated 
overall incidence of 
HFSR 
highest incidence in 
patients with renal cell 
carcinoma, lowest 
incidence in patients 
with mCRC 
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For relative risk (RR) analysis, only phase III randomized, placebo-
controlled trials were included; calculation showed an overall RR of 5.4 
(95% CI: 3.76-7.76, p<0.001) for all-grade and an RR of 41.99 (95% CI: 5.88-
299.93, p<0.001) for high-grade HFSR for regorafenib compared to placebo. 
Comparing the incidences of HFSR in patients treated with regorafenib and 
patients treated with other multi-kinase inhibitors (pazopanib, sunitinib, ax-
itinib and sorafenib), incidences of both all-grade and high-grade HFSRs 
were significantly higher for patients treated with regorafenib. 
 
 
7 Estimated costs 
Regorafenib (Stivarga®) is administered orally at a dosage of 160 mg per day, 
for the first 21 days of each 28-day cycle. It is available in the form of 40 mg 
film-coated tablets [3]. 
For Austria, no cost estimates are available yet. According to manufacturer’s 
information, the list price for a 28-day supply in the United States is $ 9,350 
[18]. Converted into euros, the monthly treatment costs for regorafenib are 
approximately € 7,035. In Switzerland, the costs for 84 tablets (sufficient for 
one month of regorafenib treatment) are CHF 5,567 [19], which equals ap-
proximately € 4,515. 
In the CORRECT trial, mean duration of treatment was 2.8 months for the 
regorafenib group [16]. Thus, three months of regorafenib treatment would 
amount to € 21,105 (U.S. price) and € 13,545 (Swiss price), respectively. Ad-
ditionally, costs for BSC and management of adverse events incur. 
 
 
8 Ongoing research 
In July 2013 a search in databases www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted; the following phase III trials 
were identified: 
 NCT01853319: an open-label phase III study of regorafenib in pa-
tients with mCRC who have progressed after standard therapy. The 
aim of this study is to provide additional information about the 
safety of regorafenib. The estimated study completion date is July 
2014. 
 NCT01786538: a randomized phase III study of oxaliplatin, fluor-
ouracil and leucovorin (FOLFOX) with or without regorafenib in 
patients with mCRC having progressed after first-line irinotecan 
plus fluoropyrimidines. The estimated study completion date is 
May 2017. 
 NCT01584830: a randomized, double-blind, placebo-controlled 
phase III study of regorafenib plus BSC versus placebo plus BSC in 
Asians with mCRC who have progressed after standard therapy. 
The estimated study completion date is May 2014. 
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 NCT01538680 (EudraCT Number: 2011-005836-25): an open-label 
phase IIIb study of regorafenib in patients with mCRC who have 
progressed after standard therapy. The primary endpoint of this 
expanded-access study will be safety. There are four study locations 
in Austria. The study completion date has not been specified yet. 
Several phase I and phase II studies assessing the use of regorafenib for the 
first-line or second-line treatment (single-use or combination therapy) of 
mCRC were identified. For example, one of those studies (NCT01875380, 
EudraCT Number: 2013-000236-94) aims to evaluate the efficacy and safety 
of regorafenib in the first-line treatment of patients with mCRC who are 
frail and/or unfit for polychemotherapy. 
Moreover, a database search showed a number of studies investigating the 
effects of regorafenib on other types of cancer such as gastrointestinal stro-
mal tumors (GIST) or hepatocellular carcinoma. 
 
 
9 Commentary 
Regorafenib (Stivarga®) was approved by the FDA in September 2012 [5] for 
patients with mCRC who have been previously treated with a fluoropyrimi-
dine-, oxaliplatin- and irinotecan based chemotherapy, an anti-VEGF thera-
py and an anti-EGFR therapy (if KRAS wild-type) [3]. In August 2013, the 
EMA granted marketing authorization for Regorafenib (Stivarga®) for the 
treatment of adult patients with mCRC who have been previously treated 
with, or are not considered candidates for, available therapies (including 
fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR 
therapy)[4].  
The CORRECT trial [16], an international, multicenter, randomized, place-
bo-controlled phase III study evaluated the efficacy and safety of regorafenib 
in patients with mCRC that progressed after administration of approved 
standard therapies. Analyses showed a gain of 1.4 months in median OS in 
the regorafenib group compared to the placebo group (HR=0.77, 95% CI 
0.64-0.94, p=0.0052). Median PFS was also improved by 0.2 months in the 
regorafenib group (1.9 months) compared to the placebo group (1.7 months), 
which results in a hazard ratio of 0.49 (95% CI 0.42-0.58, p<0.0001). The ob-
jective response rate was 1.0% in patients in the regorafenib group versus 
0.4% in patients in the placebo group, suggesting that delay of tumor pro-
gression is the primary effect of the described therapy. 41% of patients re-
ceiving regorafenib and 15% of patients receiving placebo achieved disease 
control; the median duration of stable disease was 2.0 months in the regoraf-
enib group and 1.7 months in the placebo group. 
The (small) improvements in prolonging OS and PFS survival, and the posi-
tive effects on the disease control rate are in contrast to the high incidence of 
treatment-related adverse events of any grade (93% in the regorafenib group 
versus 61% in the placebo group). This led to dose modifications in 76% 
(regorafenib group) and 38% (placebo group) of patients. Adverse events of 
grade ≥3 occurred in 54% of patients in the regorafenib group and 14% of 
patients in the placebo group. 8 cases of death in the regorafenib arm and 3 
cases of death in the placebo arm were attributed to adverse events. 
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In all clinical trials (a total of 1,100 patients received Stivarga®) 0.3% of pa-
tients had severe drug-induced liver injury with fatal outcome. Thus,  
Stivarga® prescribing information includes a boxed warning for hepatotoxi-
city [3]. Compared to other anti-neoplastic protein kinase inhibitors like 
pazopanib, sorafenib and sunitinib, the safety profile of regorafenib is simi-
lar (including labeled warnings for teratogenicity, hypertension, hemorrhag-
ic events and QTc prolongation) [20].  
The phase III study also aimed to evaluate patients’ health-related quality of 
life and health utility values by using questionnaires (EORTC QLQ-C30 
and EQ-5D) and VAS scales. Interestingly, the results in both treatment 
groups – both at baseline and at the end of treatment – were similar, show-
ing that regorafenib treatment is apparently not responsible for a decrease in 
health status and quality of life, but does not improve quality of life either. 
In the CORRECT trial, regorafenib was administered to patients who ran 
out of therapeutic options but still had good performance status [21]; 49% of 
patients (regorafenib group) and 47% (placebo group) of patients had un-
dergone ≥4 previous systemic anticancer therapies. The median age of study 
patients in both groups was 61 years, and all patients had ECOG perfor-
mance status 0 or 1. Considering the fact that the median age at diagnosis 
for colon and rectum cancer is about 69 years [11] and previous treatment 
lines also require time, it is questionable how many patients are effectively 
eligible for this new drug in third or fourth-line therapy. Especially since 
verification is still needed of regorafenib as being an appropriate therapeutic 
option for patients with a poorer performance status than ≤1.  
For future research, some questions on regorafenib need to be answered re-
garding the mechanism of action, its activity in other lines of mCRC therapy 
and the optimal management of adverse events. Furthermore, identification 
of biomarkers could help to predict the activity of regorafenib [22]. Based on 
molecular markers, subgroups of patients who may achieve significantly bet-
ter survival times on regorafenib need to be identified [23]. 
In summary, regorafenib may represent a therapeutic option for patients 
who received all approved standard therapies while maintaining a good per-
formance status. However, the modest gain in OS and PFS survival, the 
high-risk for adverse events, lack of improvements in QoL and potentially 
considerable costs of this therapy call into question whether this drug repre-
sents a viable treatment option in unselected patients.  
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